AR110947A1 - TREATMENT OF RETINA DEGENERATION THROUGH THE USE OF PROGENITING CELLS - Google Patents

TREATMENT OF RETINA DEGENERATION THROUGH THE USE OF PROGENITING CELLS

Info

Publication number
AR110947A1
AR110947A1 ARP170103380A ARP170103380A AR110947A1 AR 110947 A1 AR110947 A1 AR 110947A1 AR P170103380 A ARP170103380 A AR P170103380A AR P170103380 A ARP170103380 A AR P170103380A AR 110947 A1 AR110947 A1 AR 110947A1
Authority
AR
Argentina
Prior art keywords
cells
population
derived
postpartum
retinal
Prior art date
Application number
ARP170103380A
Other languages
Spanish (es)
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/366,947 external-priority patent/US20170080033A1/en
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AR110947A1 publication Critical patent/AR110947A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen métodos y composiciones para tratar y reducir la degeneración de la retina mediante el uso de células progenitoras y medios acondicionados a partir de células progenitoras, tales como células derivadas del posparto. Se describen, además, factores tróficos y otros agentes segregados por las células progenitoras que protegen las células de la retina e inhiben la apoptosis de las células de la retina, tales como las células fotorreceptoras. Reivindicación 1: El uso de una población de células derivadas del posparto para tratar la degeneración de la retina; el uso comprende administrar al ojo de un sujeto una población de células derivadas del posparto, en donde la población de células segrega moléculas puente, y en donde las moléculas puente se seleccionan de MFG-E8, Gas6, TSP-1 y TSP-2. Reivindicación 3: El uso de la reivindicación 1, en donde la población de células derivadas del posparto comprende células derivadas de tejido del cordón umbilical humano aisladas a partir de tejido del cordón umbilical humano sustancialmente libre de sangre.Methods and compositions are described for treating and reducing retinal degeneration by using progenitor cells and conditioned media from progenitor cells, such as postpartum derived cells. Trophic factors and other agents secreted by progenitor cells that protect retinal cells and inhibit apoptosis of retinal cells, such as photoreceptor cells, are also described. Claim 1: The use of a population of postpartum derived cells to treat retinal degeneration; the use comprises administering to the eye of a subject a population of cells derived from the postpartum, where the population of cells secretes bridge molecules, and where the bridge molecules are selected from MFG-E8, Gas6, TSP-1 and TSP-2. Claim 3: The use of claim 1, wherein the population of postpartum derived cells comprises cells derived from human umbilical cord tissue isolated from human umbilical cord tissue substantially free of blood.

ARP170103380A 2016-12-01 2017-12-01 TREATMENT OF RETINA DEGENERATION THROUGH THE USE OF PROGENITING CELLS AR110947A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15/366,947 US20170080033A1 (en) 2014-12-16 2016-12-01 Treatment of retinal degeneration using progenitor cells

Publications (1)

Publication Number Publication Date
AR110947A1 true AR110947A1 (en) 2019-05-22

Family

ID=62242613

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103380A AR110947A1 (en) 2016-12-01 2017-12-01 TREATMENT OF RETINA DEGENERATION THROUGH THE USE OF PROGENITING CELLS

Country Status (3)

Country Link
AR (1) AR110947A1 (en)
TW (1) TW201836623A (en)
WO (1) WO2018102174A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US10758571B1 (en) 2019-04-09 2020-09-01 Combangio, Inc. Processes for making and using a mesenchymal stem cell derived secretome

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013330433B2 (en) * 2012-10-09 2016-06-16 Sanbio, Inc. Methods and compositions for treatment of retinal degeneration
SG11201704268TA (en) * 2014-12-05 2017-06-29 Janssen Biotech Inc Treatment of ocular conditions using progenitor cells
EP3233096A4 (en) * 2014-12-16 2018-08-22 Janssen Biotech, Inc. Treatment of retinal degeneration using progenitor cells

Also Published As

Publication number Publication date
TW201836623A (en) 2018-10-16
WO2018102174A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
CO2017004715A2 (en) Methods and formulations to treat vascular eye diseases
EA201891152A1 (en) EXTRACELLULAR VESICULES OF NERVOUS CELLS
MX2020005547A (en) Modulators of complement activity.
MX2023007212A (en) Epinephrine spray formulations.
MX2020008680A (en) Combination therapy with apilimod and glutamatergic agents.
GT201600084A (en) (AZA) PIRIDOPIRAZOLOPIRIMIDINONAS AND INDAZOLOPIRIMIDINONAS AND ITS USE
CO2021014008A2 (en) Pharmaceutical Compounds for the Treatment of Complement-Mediated Disorders
CL2017001301A1 (en) Stabilized ophthalmic compositions of omega 3
EA201692402A1 (en) MEDICAL FORMS FOR LOCAL APPLICATION AND THEIR USE
BR112018005267A2 (en) process for performing phototherapy or retinal photostimulation, and system for performing phototherapy or retinal photostimulation
MX355770B (en) Pharmaceutical composition of ibuprofen and tramadol for ophthalmological use.
CY1124538T1 (en) USING PRG4 TO IMPROVE DYNAMIC VISUAL ACUITY AND HIGHER-ORDER ABIRATIONS
IL277599A (en) Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders
IL273531A (en) Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
MX2016016090A (en) Ophthalmic composition for the treatment of ocular infection.
ECSP15009391A (en) siARN AND ITS USE IN THE METHODS AND COMPOSITIONS FOR THE TREATMENT AND / OR PREVENTION OF EYE DISEASES
MX2023014484A (en) Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection.
AR110947A1 (en) TREATMENT OF RETINA DEGENERATION THROUGH THE USE OF PROGENITING CELLS
EA201990752A1 (en) OPHTHALMOLOGICAL COMPOSITION CONTAINING CITYCOLINE PORTABLE BY LIPOSOMA FOR TREATMENT OF GLAUCOMA
AR092842A1 (en) TREATMENT OF OCULAR INFLAMMATORY DISEASES USING LAQUINIMOD
CL2020001426A1 (en) Topical ophthalmic composition comprising dobesilic acid to treat diseases of the posterior segment of the eye.
MX2021003798A (en) Therapy with cells from human placenta and hematopoietic cells.
EA201792603A1 (en) ANGIOGENESIS USING STIMULATED PLACENTAL STEM CELLS
BR112016028561A2 (en) composition, dosage form, and methods for reducing the risk for mortality in an individual, the risk for a disease or condition in an individual, triglycerides in an individual's blood, an individual's resting heart rate, lipoprotein cholesterol non-high density in an individual, total cholesterol in an individual, apolipoprotein b in an individual blood, systolic blood pressure in an individual, and diastolic blood pressure in an individual, to prolong an individual's life, to treat hypertriglyceridemia in an individual and to increase an omega-3 index in an individual's red blood cells.
CO2018007251A2 (en) Methods and compositions for the treatment of hunter syndrome

Legal Events

Date Code Title Description
FB Suspension of granting procedure